Your browser is no longer supported. Please, upgrade your browser.
OCGN Ocugen, Inc. daily Stock Chart
Ocugen, Inc.
Index- P/E0.13 EPS (ttm)11.56 Insider Own0.30% Shs Outstand11.96M Perf Week-20.73%
Market Cap18.30M Forward P/E- EPS next Y- Insider Trans- Shs Float11.41M Perf Month-87.63%
Income-2.80M PEG- EPS next Q- Inst Own5.80% Short Float1.24% Perf Quarter-87.69%
Sales- P/S- EPS this Y76.40% Inst Trans1.76% Short Ratio0.20 Perf Half Y-88.81%
Book/sh-5.54 P/B- EPS next Y- ROA-24.50% Target Price5.00 Perf Year-95.10%
Cash/sh- P/C- EPS next 5Y- ROE46.50% 52W Range1.22 - 57.00 Perf YTD-71.15%
Dividend- P/FCF- EPS past 5Y38.20% ROI- 52W High-97.32% Beta3.11
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low25.41% ATR1.52
Employees49 Current Ratio4.00 Sales Q/Q- Oper. Margin- RSI (14)21.35 Volatility23.75% 37.68%
OptionableNo Debt/Eq- EPS Q/Q94.50% Profit Margin- Rel Volume1.96 Prev Close1.59
ShortableYes LT Debt/Eq- Earnings- Payout0.00% Avg Volume719.11K Price1.53
Recom3.00 SMA20-81.09% SMA50-85.98% SMA200-85.18% Volume1,398,958 Change-3.77%
Oct-09-19 07:30AM  Ocugen Announces Share Repurchase Program GlobeNewswire +34.38%
Oct-07-19 07:00AM  Ocugen Announces Amendment to Asset Purchase Agreement GlobeNewswire
Oct-01-19 07:30AM  Ocugen Appoints Sanjay S. Subramanian, MBA, as Chief Financial Officer GlobeNewswire -23.16%
Sep-30-19 04:05PM  Ocugen to Present at Three Upcoming Conferences GlobeNewswire -70.68%
08:30AM  Ocugen and CanSinoBIO Enter Strategic Partnership for Gene Therapy Co-Development and Manufacturing Business Wire
07:30AM  Ocugen Announces Completion of its Merger with Histogenics to Create Nasdaq-Listed Clinical-Stage Company Developing Novel Ocular Gene Therapies and Biotherapeutics Business Wire
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.